Asthma, COPD Tied to Worse COVID-19 Outcomes
Individuals should continue to receive asthma care and take asthma medications during the pandemic.
COPD Information Center
Exploring the Use of Omics to Eliminate Sex and Gender Differences in COPD
Although it has become widely accepted that COPD encompasses a range of phenotypes, the development of a precision medicine approach has been slow.
Asthma, COPD Do Not Increase Mortality Risk in Patients With COVID-19
Asthma and chronic obstructive pulmonary disease (COPD) do not appear to increase the risk of mortality in patients with COVID-19.
Long-Term Exposure to Particulate Matter Increases CV Mortality Risk in COPD
In adults with COPD, long-term exposure to PM2.5 was associated with an increased risk for cardiovascular mortality.
Indoor Mold Exposure, Anti-Aspergillus Antibodies May Hold Clinical Implications for COPD
Indoor mold exposure and the presence of anti-Aspergillus antibodies may be linked to worsened lung function during exacerbations in COPD.
ACA Improved Uninsurance Rates in COPD and Asthma, but Not Affordability
While the ACA effectively reversed coverage losses for patients with airway disease, neither care affordability nor disparities improved for these patients.
E-Cigarette Use May Increase COPD Risk
Electronic cigarette (e-cigarette) use may be associated with an increased risk of chronic obstructive pulmonary disease (COPD).
Effects of COVID-19 Lockdown in Spain on Patients With COPD
In patients with COPD, lockdown for coronavirus disease 2019 (COVID-19) was associated with a reduction in exacerbations and an improvement in symptoms.
Potential Beneficial Effects of Antidiabetic Medications on COPD Exacerbations
Duration-dependent beneficial effects of metformin, sulfonylurea, and thiazolidinedione use on COPD exacerbation have been observed in patients with COPD and diabetes.
Reduced All-Cause Mortality in COPD With Budesonide/ Glycopyrrolate/ Formoterol
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate may reduce the risk of death compared with glycopyrrolate/formoterol fumarate in patients with COPD.
Inhaled Corticosteroid Therapy May Reduce Lung Function Decline in COPD
The adjusted rate of decline in predose trough FEV1 during 52 weeks in theResearchers used a substudy of the Phase 3 ETHOS study to evaluate lung function decline in patients with inhaled corticosteroid-containing therapies vs glycopyrrolate/formoterol fumarate metered dose inhaler.
Revefenacin Plus Formoterol Via Nebulization Improves Lung Function Response in COPD
Once-daily revefenacin when administered via a jet nebulizer with formoterol was well tolerated and associated with greater lung function response compared with formoterol alone in patients with COPD.
COVID-19 With COPD: Fewer Hospitalizations, But Greater Mortality
Chronic obstructive pulmonary disease may be associated with higher rates of mortality in patients with coronavirus disease 2019.
HRRP Implementation Reduced 30-Day All-Cause Readmission Rates in COPD
Implementation of the Hospital Readmission Reduction Program was associated with a decrease in 30-day readmissions in patients with COPD following their hospital discharge.
ATS Issues Recommendations for Noninvasive Ventilation in COPD
Recommendations are presented for the use of noninvasive ventilation for patients with COPD and chronic hypercapnia in an American Thoracic Society clinical practice guideline.
Acute COPD Exacerbation Frequency May Not Be Accurate Guide for Treatment
The 12-month history of acute exacerbations used to guide most COPD treatment relies on an unstable frequent exacerbator phenotype.
Dupilumab Improves Lung Function in CRSwNP and Comorbid Asthma and COPD Features
Treatment with dupilumab led to significant improvements in lung function by 16 weeks and up to 24 weeks in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma plus clinical features of COPD.
Breztri Aerosphere Approved as Triple-Combination Therapy Inhaler for COPD
The FDA has approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate; AstraZeneca) for the maintenance treatment of chronic obstructive pulmonary disease.
Triple Inhaled Therapy Aids in Moderate-to-Very Severe COPD
Triple therapy, including glucocorticoid at either of 2 dose levels, is beneficial for moderate-to-very severe chronic obstructive pulmonary disease.
Electronic Communication From Pulmonologist to PCP Beneficial in COPD Care
Preemptive, patient-specific electronic messages from pulmonologists to primary care physicians improved guideline concordant care in COPD.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in COPD Information Center
Loading... 
Loading...